PF-Atlas › Clinical Trials › NCT02269189

Safety, Tolerability and Pharmacokinetics of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis Patients

BIIL 284 BS, high dose · Phase 1

Registry ID
NCT02269189
Phase
Phase 1
Status
Completed
Drug / intervention
BIIL 284 BS, high dose
Sponsor
Boehringer Ingelheim
Start
2002-04
Enrollment
36

About this trial

Safety, tolerability and pharmacokinetics following repeated doses (15-day dosing)

View NCT02269189 on ClinicalTrials.gov →

Explore related

All BIIL 284 BS, high dose trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT02269189 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.